Mode
Text Size
Log in / Sign up
Phase 4 Completed N=122 Randomized Quadruple-blind Prevention

Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections

Source: ClinicalTrials.gov NCT01734161 ↗
Enrolled (actual)
122
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Incidence of Post-operative Nausea and/or Vomiting — 29; 24 Participants
◆ Published Evidence
Emerging
13citations · ~2 / year
The effect of intravenous dexamethasone on postoperative nausea and vomiting after Cesarean delivery with intrathecal morphine: a randomized-controlled trial.
Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2020 · Open access · Likely link

Summary

Patients who present for scheduled (non-emergent) cesarean section will be given either intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal anesthetic. The investigators will then compare the incidence of nausea and vomiting and the use of rescue anti-nausea medications in both groups. Our hypothesis is that patients receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours following surgery.

Linked Publications

  • The effect of intravenous dexamethasone on postoperative nausea and vomiting after Cesarean delivery with intrathecal morphine: a randomized-controlled trial.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2020 · 13 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Post-operative Nausea and/or Vomiting
29; 24

Eligibility Criteria

Inclusion Criteria

  • Women aged 18-46 presenting for scheduled primary or repeat cesarean sections and have consented to study

Exclusion Criteria

  • allergy to dexamethasone or morphine
  • history of gastrointestinal disease
  • history of severe nausea during pregnancy (hyperemesis gravidarum)
  • use of anti-emetic in the past 24 hours
  • history of gestational diabetes or diabetes mellitus
  • history of hypertension prior to or during pregnancy
  • presence of non-viable fetus
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01734161) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search